Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

April 11, 2024

https://www.globenewswire.com/news-release/2024/04/11/2861425/30757/en/Dar%C3%A9-Bioscience-Announces-Publication-in-Contraception-of-Positive-Efficacy-and-Safety-Findings-from-a-Pre-Pivotal-Postcoital-Test-Study-of-Ovaprene-an-Investigational-Hormone-Free.html

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women

Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.